NJ-PHYSICIANS’-EDUCATION
24.2.2021 19:15:05 CET | Business Wire | Press release
As the leading go-to resource for continuing medical education (CME), Physicians’ Education Resource®, LLC, (PER®), has been committed to improving the care for patients with breast cancer by educating the treatment team for nearly four decades. This commitment is more than professional, but also deeply personal. This annual marquee CME conference has been family-led since the beginning and continues to incorporate that family spirit into 2021 in the virtual setting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005893/en/
Traditionally hosted as a live marquee meeting, this year’s 38th Annual Miami Breast Cancer Conference® has transformed into a live-broadcast virtual and interactive experience leveraging new online meeting technologies. This year, the conference is more than Miami , and will bring the educational experience directly to health care professionals online.
For 37 years, the historic multidisciplinary Miami Breast Cancer Conference® has been a family-led annual meeting. By combining the conference’s legacy with the Hennessy family spirit and commitment infused into the DNA of MJH Life Sciences™, the parent company of PER®, this year’s meeting will continue to focus on improving the care of patients with breast cancer. The annual conference has become a landmark meeting that serves as the go-to resource for health care professionals to learn about the most important advancements in breast cancer treatment and how to translate these into clinical care.
“In its 38th year, whether this is your first time or your 31st time attending, PER® welcomes you as part of the Miami Breast Cancer Conference® family,” said Phil Talamo, CHCP, president of PER®. “Our community is full of dedicated oncologists, surgeons, pathologists, nurses, and more who are committed to elevating patient care. We know that it takes more than a team to treat breast cancer – it takes a family. During this year’s conference, we will virtually come together with a shared purpose of driving contemporary patient care using strategies that you hear on Friday and use on Monday.”
This year’s 38th Annual Miami Breast Cancer Conference® will continue this tradition increase the use innovative virtual technology to deliver the robust educational programming and top-notch presentations for which this conference is known for. New in 2021, PER® has expanded its afternoon programming to the full healthcare team with additional tracks on pathology, radiation oncology, and oncology nursing. To accommodate its international learners in European time zones, an international track will also be offered. This will broaden the Conference’s impact and bring vital members of the treatment team into the Miami Breast Cancer Conference family, united in the approach to improve the care of patients with breast cancer.
Additionally, this year’s expanded virtual program will feature world-class tumor board panels, multidisciplinary meet-the-expert sessions, case discussions, poster sessions, a video surgical library, lively Medical Crossfire® exchanges, and more. Included among the many important clinical and practical topics on the agenda are novel therapeutic targets, contemporary management issues, oncology care in the COVID-19 era, practical application of genomics, precision medicine, and more.
For more information and to register, click here.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. Although it is expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences ™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005893/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
